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Introduction
There is a growing epidemic of diabetes mellitus, type
2 in particular, in the Asia-Pacific region.1 Accord-
ing to current estimates, this region has the largest
diabetic population in the world—namely, 47.3 million,
which is 46% of the global burden of diabetes.2
Population-based surveys from Asia show a wide range
of prevalence rates of diabetes mellitus: from 1.3 %
in Vietnam to 24.2% in certain Indian urban com-
munities.3-5 No doubt some of the reasons for the vari-
ability are differences in the age range surveyed, study
methodology, sampling techniques, and criteria used
to classify diabetes mellitus. Nevertheless, there is a
rapidly increasing trend in the prevalence of the dis-
ease in Asian countries. For example, the prevalence
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has increased approximately three-fold, from 0.8% to
2.3%, between 1986 and 1994 in China.6 More recent
data from certain Chinese cities suggest this increase
may be even more pronounced, with a prevalence of
as high as 9.2% in Hong Kong.7 The epidemiological
transition from life-threatening infectious disease
towards more chronic conditions, ‘westernisation’ in
diet and lifestyle practices, and effects of ‘thrifty genes’
together probably account for this dynamic epidemic
of diabetes mellitus in Asia.2
Diabetes is a major source of morbidity, mortality,
and economic cost to society. Patients with diabetes
are at risk of the development of acute metabolic
complications such as diabetic ketoacidosis, hyper-
glycaemic hyperosmolar nonketotic coma, and hypo-
glycaemia. They are also at risk of experiencing chronic
complications such as atherosclerotic diseases, retin-
opathy, nephropathy, neuropathy, and foot ulceration,
as well as other general medical conditions unrelated
to the acute or chronic complications specific to dia-
betes. It has been estimated that the annual per capita
health care expenditure in the United States in 1997
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was four-fold for people with diabetes when compared
with the general population.8
This article reviews the chronic complications of
diabetes mellitus and considers the scientific basis,
clinical care, economic impact, and public health
implications of these co-morbidities on patients,
doctors, and health care organisations in Asia.
The glucose hypothesis
Diabetes mellitus is a metabolic disorder character-
ised by hyperglycaemia and alterations in fat and
protein metabolism, and the occurrence of a specific
set of chronic complications. The plasma glucose
cut-off levels for diagnosing diabetes mellitus rest
firmly in their association with diabetic complications
such as retinopathy.9 The tacit recognition of the
close relationship between hyperglycaemia and chronic
complications has led to the ‘glucose hypothesis’,10,11
which proposes that hyperglycaemia is directly, or
indirectly, related to the development or progression,
or both, of diabetic complications, including the
microvascular conditions of retinopathy, nephropathy,
and neuropathy.12 For macrovascular or atherosclerotic
complications of diabetes mellitus, a subanalysis of
the Framingham Heart Study cohort has demonstrated
a clear dose-response association between glycated
haemoglobin levels and the prevalence of cardio-
vascular disease.13 In addition, recent interventional
studies in patients with type 114 and type 215 diabetes
mellitus have provided strong support for the glu-
cose hypothesis. In the Diabetes Control and Compli-
cations Trial (DCCT), intensive therapy reduced the
development and progression of all complications by
approximately 50%.14 This uniform salutary effect
on retinopathy, nephropathy, and neuropathy further
suggests that hyperglycaemia may play a similar role
in the pathogenesis of these complications.11
Exactly what the pathogenetic mechanism is and
how it works are still unanswered questions. Tradi-
tionally, there have been two major putative pathways:
the aldose reductase–sorbitol and the glycation mod-
els. Results of animal studies support the former model,
but results from human studies have been less con-
vincing.16-18 The efficacy of a potent protein glycation
inhibitor was reported in a diabetic animal model in
1986,19 but its effectiveness remains to be proven in
an ongoing human clinical trial. A third pathway by
which hyperglycaemia may cause long-term vascular
complications, has recently been described.20 This
model suggests that the activation of the β2-isoform
of protein kinase C in vascular tissue is a key step in
the cascade of events through which glucose triggers
diabetic complications.10,20
The available evidence indicates that chronic
hyperglycaemia is a causal link between diabetes
mellitus and diabetic complications. However, the
precise mechanism by which hyperglycaemia may
cause complications in diabetic individuals remains
to be clearly defined. Data from familial21 and
ethnic22 clusterings of diabetic complications suggest
that the susceptibility to hyperglycaemia-induced
tissue damage may be determined by genetic factors.
Candidate genes such as the aldose reductase gene23-25
and fibrinogen gene,26 which confer susceptibility to
microangiopathic and macroangiopathic complications
respectively, have been identified in various sib-pair
linkage analyses26 or case-control studies.23-26
Microvascular manifestations
Diabetes mellitus is the leading cause of blindness,
end-stage renal disease, and non-traumatic amputation
in industrialised countries.27,28 These conditions are
the direct end-points of microvascular complications
that are specific to diabetes and which include
retinopathy, nephropathy, and neuropathy. The risks of
these conditions developing can be significantly re-
duced by optimising glycaemic control and if they are
detected and treated early through patient education
and regular screening.14,15,28
Retinopathy
Retinopathy is an important complication of diabetes
mellitus in the Asian population. The prevalence be-
tween 1990 and 1996 for patients with newly diag-
nosed type 2 diabetes mellitus has been estimated to
be 22% in Hong Kong,29 and a population-based study
performed in China in 1986 showed a prevalence of
31%.30 Randomised controlled trials such as the
DCCT and the United Kingdom Prospective Diabetes
Study (UKPDS) have shown conclusively that improv-
ing glycaemic control can decrease the incidence of
diabetic retinopathy.14,15 This concept is also supported
by prospective follow-up studies among Japanese
and Chinese patients with type 2 diabetes mellitus.31,32
Furthermore, the DCCT also demonstrated that strict
glucose control retards the progression of background,
non-proliferative retinopathy.14 Thus, primary and
secondary prevention of retinopathy can be effectively
accomplished by intensive glycaemic management and
regular ophthalmological screening.14,15
Proliferative retinopathy and macular oedema are
late complications in the continuum of diabetic retinal
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disease. Research on tertiary prevention has shown that
these conditions can be treated using laser therapy,
which reduces significantly the incidence of severe
visual loss and blindness.33 Despite these findings, only
35% to 60% of American diabetic people currently
undergo annual ophthalmological screening.34 There
is no corresponding estimate for Asian countries, where
the rate is conceivably even lower due to the long
latent phase of retinopathy, a lack of health promo-
tion activities, and scarce availability of resources and
services. In Hong Kong, a recent cross-sectional study
of 629 asymptomatic type 2 patients revealed that 19%
and 3% of subjects had non-proliferative retinopathy
and proliferative changes that required laser treat-
ment, respectively.35 Thus, it is recommended that all
diabetic patients undergo an annual dilated fundal
examination to screen for diabetic retinopathy.28,36
Nephropathy
Diabetic nephropathy (ie comprising microalbuminuria
to end-stage renal disease) develops in approximately
35% of patients with type 1 diabetes mellitus and
between 15% and 60% of patients with the type 2
disease.37 It is the leading cause of chronic renal fail-
ure worldwide and is responsible for about one third
of patients who undergo dialysis.38 One of the initial
markers of this condition is microalbuminuria, which
indicates an increased risk of progression to nephro-
pathy as well as an elevated risk of cardiovascular
events.39 The natural course of diabetic nephropathy
is such that once overt nephropathy develops, renal
function progressively declines and culminates in
end-stage renal disease.40,41 Hence, as with retinopathy,
optimal glucose control is of paramount importance as a
primary preventive measure against the development
of diabetic nephropathy.14,15
In addition, all diabetic people should be screened
for proteinuria and microalbuminuria annually.28,36
There are various ways of performing urine tests;
Table 1 shows the diagnostic criteria for albuminu-
ria.42 Measuring the random, spot albumin to creat-
inine ratio is a simple technique that can be used as a
screening test.28 Because of significant variations in
urine albumin excretion, however, it is recommended
that if the results of the first test are positive for
albumin, the test be repeated for confirmation. If the
second test gives negative results, a third test should
be performed. Two of the three tests should give posi-
tive results and other potential aetiologies should be
excluded before the presence of microalbuminuria
can be concluded.28,42 If albuminuria is diagnosed, treat-
ment with an angiotensin-converting enzyme (ACE)
inhibitor should be considered. This treatment can
reduce albuminuria and delay or possibly halt the
progression to nephropathy, independent of its blood
pressure–lowering effect.43 Aggressive blood pressure
control is also of vital importance in preventing
progression of declining renal function. Maintaining
the blood pressure is the only modality that has
consistently been shown to be effective in halting pro-
gression to overt nephropathy and renal failure.44
Although absolute target blood pressure levels for
patients with diabetic nephropathy have not been well
delineated, there is a clear association between blood
pressure and the rate of progression of diabetic renal
disease, in both Caucasian and Chinese populations.44,45
There has recently been a renewed interest in
the pathogenetic role of hyperlipidaemia in diabetic
nephropathy.46 Results from a prospective trial per-
formed in Hong Kong have shown that effective
normalisation of hypercholesterolaemia might retard
the progression of nephropathy in patients with
type 2 diabetes mellitus.47 The full potential of lipid-
lowering therapy remains to be established by longer-
term studies with a larger sample of individuals.
Neuropathy
Diabetic patients have an increased risk of the
development of neuropathy. Foot ulcers may develop,
mainly because of the abnormal distribution of
pressure owing to peripheral neuropathy. A study in
the United States showed that one half of a group of
patients who had had type 2 diabetes mellitus for more
than 15 years also had diabetic neuropathy.27 Even
among newly diagnosed cases of type 2 diabetes
mellitus, retrospective data from Hong Kong suggest
a prevalence of neuropathy of approximately 13%.29
As with retinopathy and nephropathy, a policy of
Table 1. Cut-off values for microalbuminuria using different types of urine test 42
Test Units Normal Microalbuminuria Macroalbuminuria
24-hour mg/d <30 30-300 >300
Overnight µg/min <20 20-200 >200
1st morning
or random test:
albumin mg/L <20 20-200 >200
albumin : creatinine mg/mmol <2.5 for men - -
<3.5 for women - -
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strict glycaemic control reduces the incidence of neuro-
pathy in patients with either types 1 or 2 diabetes
mellitus.14,15 The early detection of diabetic neuro-
pathy results in fewer hospitalisations of patients
with foot ulcers and fewer lower-extremity amputa-
tions.48 Accordingly, all diabetic patients should
regularly undergo sensory testing and be screened for
foot ulceration at regular intervals. In the absence of
clear evidence, consensus expert opinion suggests
annual sensory examination and opportunistic screen-
ing for foot ulceration at each clinical encounter.28,36
Educating patients and increasing physician surveil-
lance regarding foot care and risk factors for amputa-
tion have been tested in a randomised controlled
trial and a prospective study. Both studies reported
significant reductions of serious foot ulceration in the
intervention groups.49,50
Macrovascular manifestations
Diabetes mellitus is an independent risk factor for
the development of atherosclerosis.51 On the other
hand, atherosclerotic or macrovascular disease is
responsible for more than 50% of all deaths in patients
with type 2 diabetes mellitus.27 Cardiovascular dis-
ease accounts for most cases of diabetic macrovascular
complications; the remainder are caused by cerebro-
vascular events and peripheral vascular disease.52
The results from a population-based study suggest that
there is a 10-fold increase in coronary artery disease
among Chinese diabetic patient when compared with
the characteristically low rate among non-diabetic
controls.30
While hyperglycaemia has been conclusively
shown to be the causal link between diabetes mellitus
and microvascular complications, its association with
macrovascular manifestations is much more tenuous,
as reflected by the results of the UKPDS and the
DCCT.14,15 In the UKPDS, the number of macrovascular
events greatly outnumbered that of microvascular
complications, but the difference was found to be non-
significant. This result was not wholly unexpected
given the multifactorial nature of cardiovascular dis-
ease. Factors such as hypertension, hyperlipidaemia,
and tobacco use contribute to the development of
atherosclerosis in diabetic people. Hence, hyper-
tensive control, lowering lipid levels, and smoking
cessation are important preventive measures that
can help prevent the development of macrovascular
diabetic complications.28,36
Hypertension develops in people with type 2
diabetes mellitus at twice the rate of those who are
non-diabetic.53 Hypertension is a major contributor
to atherosclerotic diseases and can lead to a more
rapid progression of nephropathy and renal failure.54,55
The UKPDS has demonstrated that a policy of
rigorous blood pressure control reduces the risk of
macrovascular and microvascular complications in
patients with type 2 diabetes mellitus, even more so
than the effect of strict glycaemic management.44
Thus, screening and treating hypertensive diabetic
patients are essential. There is no clear evidence
to support a specified goal in blood pressure
control, although the UKPDS used an upper limit of
150/85 mm Hg as its definition of stringent hyper-
tensive control.44
Elevated serum lipid levels are also a significant
risk factor in the development of macrovascular dis-
eases in patients with type 2 diabetes mellitus. There
are no large randomised controlled trials reported that
evaluate the effectiveness of giving lipid-lowering treat-
ment to diabetic patients who have an abnormal lipid
profile and are at risk of heart disease. However,
small subgroup analyses of two studies of high-risk
diabetic individuals have shown that lowering
low-density lipoprotein–cholesterol levels leads to
a"significant reduction in cardiovascular mortality.56,57
Given the high prevalence of cardiovascular disease
in diabetic patients and its associated morbidity and
mortality,27 a conservative approach would be to
screen for hyperlipidaemia annually and to treat the
condition as soon as it is detected.
It is well known that tobacco use and diabetes
mellitus are synergistic risk factors in the develop-
ment of cardiovascular disease.58 Smoking is also
responsible for a whole spectrum of other diseases,
which include numerous cancers and chronic lung
disease. It follows that all possible measures should
be used to prevent people from starting the habit,
and to encourage smokers to stop, especially in the
diabetic population.28,36
The traditionally ‘soft’ cardiovascular risk factors
of obesity and a sedentary lifestyle may be particu-
larly important in South Asian (Indian, Pakistani, and
Bangladeshi) diabetic patients. Observational studies
have demonstrated higher mortality and morbidity
rates of cardiovascular disease in overseas migrants
of South Asian descent who have diabetes, compared
with other ethnic groups.59 It has been hypothesised
that the high mortality rate is due to metabolic dis-
turbances related to insulin resistance.59 Results from
the United Kingdom have confirmed the existence of
insulin resistance syndrome (glucose intolerance,
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hyperinsulinaemia, hypertension, low levels of plasma
high-density lipoprotein–cholesterol, and high levels
of triglycerides), which is especially prevalent in South
Asians and which is associated with a pronounced
tendency to central obesity.59 Thus, the management
of obesity and increased physical exercise represent
the most ideal preventive measures against diabetes
mellitus and coronary artery disease in this vulnerable
population.
The economic burden of diabetes mellitus
and its complications
Diabetes mellitus is a major and increasing cause of
chronic ill health and premature mortality in almost all
Asian countries,1-7 and results in rising costs because
of absence from work and health care expenses.8,60 To
facilitate service planning and to allocate public health
resources appropriately, there should be reliable
estimates and projections of the economic costs
associated with diabetes mellitus, its complications,
and its co-morbidities. This is especially true in Asian
countries where there is a dynamic, growing epidemic
of diabetes.1-3
There are two main approaches to investigating
the economic impact of diabetes mellitus and its com-
plications. The first approach uses disability-adjusted
life-years (DALYs) to measure the intangible costs
associated with the disease, and combines the healthy
life-years lost as a result of premature mortality with
those lost due to disability or ill health. This method is
valuable, because a substantial portion of health care
expenditure is directed towards improving the quality
of life and life expectancy in diabetic individuals.
The largest relevant study that has been published so
far was performed by the World Bank in 1993.61 Their
global study investigated the DALYs lost due to vari-
ous diseases, including diabetes, and estimated that
1362 million DALYs were lost worldwide as a result
of all illnesses in 1990. Of these, diabetes mellitus and
its complications accounted for 7.97 million DALYs,
as shown in Table 2.61 The majority of losses were
incurred in developing nations (eg China and India).
When comparing the DALYs lost with per capita health
expenditures in different countries, the data suggested
that the countries in which 80% of the DALYs lost
were attributable to diabetes mellitus shared only 13%
of the world’s health care expenditures.60 For exam-
ple, with an annual per capita expenditure on health
care of US$21, the population of India lost 1.9 million
DALYs because of diabetes mellitus. In contrast, es-
tablished market economies such as the Organisation
for Economic Cooperation and Development nations,
which account for 15% of the world’s population and
87% of its health care resources, together lost only 1.3
million DALYs because of diabetes mellitus.60 In short,
the heavy economic burden of this life-long condition
due to loss of quality of life and premature mortality is
concentrated in those countries with the lowest health
care budgets, many of which are in Asia.60,61 Despite
some criticisms and caveats about methodological
issues, the World Bank study provides strong support
for the need to improve the provision of diabetic health
services in Asian countries, particularly in those under-
going rapid demographic and economic development.61
The second and most frequently employed technique
used to evaluate the economic implication of diabetes
is the cost-of-illness approach, which examines the
direct and indirect costs associated with the condition.
In Asia, there has been little systematic effort to
conduct comprehensive examinations of the economic
consequences of diabetes mellitus. In the United States,
direct medical expenditures attributable to diabetes
mellitus in 1997 totalled US$44.1 billion. The
breakdown was as follows: US$7.7 billion because of
diabetes and acute glycaemic care, US$11.8 billion
because of the excess prevalence of related micro-
vascular and macrovascular complications, and
US$24.6 billion because of the excess prevalence of
general medical conditions.8 Of these direct costs, 62%,
25%, and 13% were related to in-patient care, ambu-
latory services, and long-term care, respectively.
Two thirds of all medical costs were borne by the
elderly (aged >65 years) population. Attributable in-
direct costs totalled US$54.1 billion and comprised
US$17.0 billion due to premature mortality and
US$37.1 billion due to disability. Furthermore, total
medical expenditure incurred by diabetic patients was
US$10 071 per capita, compared with US$2669 for
the non-diabetic population.8 Likewise, the economic
Table 2. The number of diability-adjusted life-years lost as a result of diabetes mellitus in 199061
Country/region  Disability-adjusted life-years (x106) Health expenditure per capita (US$)
China 0.77 11
India 1.87  21
Other Asian countries 1.15 61
Established market economies 1.33  1860
Worldwide 7.97 329
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burden of diabetes mellitus in Asia is enormous,
anticipated by the prevalence and incidence of the
disease and is  predicted to increase more in Asia than
in the industrialised western nations in the next few
decades.1-3,60 It has been estimated that the overall
health care costs due to diabetes mellitus in the year
2010 will be doubled when compared with 1990.60
Implications of public health and health care
Given the very serious clinical and economic ramifica-
tions of diabetes mellitus, it is imperative that doctors,
public health practitioners, and policy makers
vigorously pursue health care strategies and medical
innovations that can delay the onset and slow the
progression of the disease and its complications. One
strategy is to reduce the incidence of diabetes mellitus
in Asia. While genetic factors have a definite role
in the development of the disease, there are also
environmental and lifestyle risk factors, such as a
high saturated fat diet, obesity, and lack of physical
activity.1,3 These three risk factors are currently recog-
nised as the most potentially modifiable. Although
implementing lifestyle changes, as with any behav-
ioural change, poses a difficult challenge, doing so is
essential to improving public health and lessening the
impact of the Asian diabetes epidemic.
A second, complementary strategy is to focus on
the primary and secondary prevention of diabetic
complications in individuals who have already devel-
oped diabetes mellitus. The DCCT and UKPDS have
shown that optimal glycaemic control is the most ideal
primary preventive measure against the development
of complications.14,15 It is also well known that
treating complications such as eye and limb diseases,
heart disease, neuropathy, and nephropathy contribute
the most to the costs of diabetes care.62 Once compli-
cations develop, the indirect costs of disability and
premature mortality increase exponentially; hence, the
secondary prevention of diabetic complications may
be highly effective in reducing the health care burden
of diabetes mellitus in general.63 Such secondary
preventive measures include a policy of strict blood
pressure control,44 institution of ACE inhibition in
microalbuminuric patients,43 normalisation of hyper-
lipidaemia,47,56,57 smoking cessation,28,36 and regular
screening for all diabetic complications.28,36
A third major component in combating the dia-
betes epidemic in Asia involves health promotion and
patient education. The reasons are two-fold. Firstly,
there are many undiagnosed cases of diabetes mellitus
in Asia. For example, the ratio of undiagnosed to
diagnosed cases in Vietnam and Bangladesh is as high
as 4:1.1,4 There is thus a serious potential for severe
diabetic complications to occur because of prolonged
undiagnosed hyperglycaemia. Secondly, the clinical
presentation of type 2 diabetes mellitus and its com-
plications are usually insidious and have a long latent
period. As a consequence, patient compliance with
regular follow-up and screening may be poor because
the conditions are asymptomatic. Patients there-
fore need to be adequately informed of the necessity
and benefits of these clinical interventions. Financial
constraints in some developing Asian economies, how-
ever, may render optimal diabetes care impossible.
Even when the services are provided, they may be
inadequate or inaccessible to patients.34
Finally, increases in both the cost of providing
quality diabetes care and the number of people devel-
oping the disease have led to a search for more cost-
effective models of care. One such model is the ‘shared
care’ approach, the efficacy of which has been well
documented.64,65 In this approach, both specialists
and primary care doctors participate in the planned
delivery of care; they also exchange information over
and above routine discharge and referral notes. Hall-
marks of effective and efficient shared-care schemes
include computerised central recall with prompts for
patients and their family doctors, shared records, im-
proved communication between doctors and patients,
flexible and agreed management plans, the possibility
of patients moving up and down the levels of care,
and a fail-safe system of coordinated care.64,65
Conclusion
The growing Asian epidemic of diabetes mellitus, and
its implications in terms of morbidity, mortality, and
economic costs of its complications, calls for urgent
attention from clinicians, public health officials,
and governments. Doctors should be encouraged to
implement primary and secondary preventive  meas-
ures that have been proven to be effective, while
community health workers should actively promote
diabetes education to diagnosed patients as well as to
the general public. Furthermore, government agencies
should increase and redirect appropriate human and
financial resources towards services for the diabetic
population. When the demand exceeds the realistic
possibility of supplying the needed services, which is
the case in many developing countries in Asia, the
limited health care resources must be rationally allo-
cated to programmes of proven efficacy.66 This is a
tough challenge indeed, and the decisions made will
influence the quality of diabetes care in Asia.
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